Prevention First

Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.

Read more

Vaccine Market Access in the EU

How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access

Find out more

Vaccines Europe at a glance

Vaccines Europe acts as the cohesive voice of the Europe-based vaccine industry sector and is a trusted partner for public authorities. Find out more about our association and contribution to Europe.

Start Prezi

The vaccine industry
in figures

With 47% growth in R&D investment over the past eight years and over 70% of current R&D projects based on new antigens and new combinations, Vaccines Europe members highly contribute to innovation.

Find out more

An industry for healthy lives

As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe and is currently expanding to SMEs.
Find out more about our services, the opportunites we offer and how to become a member.

Find out how to become a member

Latest News


Prevent Hepatitis – World Hepatitis Day – 28 July 2015

2015 07 28 Written by Vaccines Europe

Today is World Hepatitis Day. The World Health Organisation (WHO) estimates that every year viral hepatitis kills 1.4 million men and women on average, with many more becoming newly infected. This is why, the theme of this year’s campaign is Prevent Hepatitis. Achieving this goal means not only building appropriate awareness among the general public and healthcare staff on how different types of hepatitis infection can be prevented, but also on how to improve access to and delivery of the core services that improve vaccinations against it, blood and injection safety, and reduced harm. With better prevention, 4000 lives can be saved per day.

Join the debate on Twitter using the hashtag #PreventHepatitis

And visit


World first Malaria Vaccine receives positive scientific opinion from EU regulators

2015 07 24 Written by Vaccines Europe

The European Medicines Agency has today adopted a positive scientific opinion for the world’s first malaria vaccine, submitted for approval by vaccine manufacturer GSK. The vaccine was developed in partnership with the PATH Malaria Vaccine Initiative, and is the first candidate vaccine for the prevention of malaria to reach this milestone. The vaccine has been designed to prevent malaria caused by the most prevalent parasite in sub-Saharan Africa. Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected mosquitoes. In 2013, malaria caused an estimated 584 000 deaths, mostly among African children.  Read more…

EU Commission/EIB launch financing tool dedicated to R&D in infectious diseases

2015 07 14 Written by Vaccines Europe

Vaccines Europe welcomes the new financing tool dedicated specifically to R&D in infectious diseases that has been launched by the European Commission and the European Investment Bank.

This new instrument, InnovFin Infectious Diseases, was  established within the InnovFin – EU Finance for Innovators family of instruments and will provide loans to high-risk projects in the area of infectious disease R&D and reinvigorate and attract co-investment from other investors by incentivising R&D activities for an uncertain market. It can be accessed by small, medium and large companies, research infrastructures, universities, non-profit organisations, and Special Purpose Vehicles (SPV) established and operating in one or several of the EU Member States and Associated Countries. Read more…

See all News